A DNA vaccine for the prevention of Ebola virus infection

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 3, 2008, Pages 285-293

  Dery M ^a   Bausch, D G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EBOLA VACCINE; PLACEBO;

ANTIBODY RESPONSE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DNA IMMUNIZATION; DRUG ACTIVITY; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EBOLA VIRUS; FEVER; HEADACHE; HERPES ZOSTER; HUMAN; INJECTION SITE DISCOLORATION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MYALGIA; NAUSEA; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISCOLORATION; STRUCTURE ACTIVITY RELATION; VIRUS HEMORRHAGIC FEVER; VIRUS STRAIN;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES, DNA;

EBOLA VIRUS;

EID: 44849134830     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. 316630 Immunization for Ebola virus infection. Xu L, Sanchez A, Yang ZY, Zaki SR, Nabel EG, Nichol ST, Nabel GJ NAT MED 1998 4 1 37-42
2. 320262 DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C Virology 1998 246 1 134-144
3. 333344 Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV Nat Med 1998 4 4 397-402
4. 392566 New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Fallaux FJ, Bout A, Van Der Velde I, Van Den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, Van Ormondt H, Van Der Eb AJ, Valerio D et al Hum Gene Ther 1998 9 13 1909-1917
5. 419864 Development of a preventive vaccine for Ebola virus infection in primates. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ Nature 2000 408 6812 605-609
6. 450874 Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, Stout R et al Proc Natl Acad Sci USA 2001 98 19 10817-10822
7. 513839 Vical and NIH developing Ebola vaccine. Vical Inc PRESS RELEASE 2003 November 18
8. 513907 NIAID Ebola vaccine enters human trial. National Institutes of Health PRESS RELEASE 2003 November 18
9. 513949 Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Sullivan NJ, Geisbert TW, Gelsbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ Nature 2003 424 6949 681-684
10. 544974 A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Murakami P, Pungor E, Files J, Do L, van Rijnsoever R, Vogels R, Bout A, McCaman M Hum Gene Ther 2002 13 8 909-920
11. 746507 Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA et al J Infect Dis 2006 194 12 1650-1660
12. 782329 A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA et al Clin Vaccine Imunol 2006 13 11 1267-1277
13. 782330 Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M et al PLoS Med 2006 3 6 e177
14. 782331 Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Sheets RL, Stein J, Manetz TS, Andrews C, Bailer R, Rathmann J, Gomez PL Toxicol Sci 2006 91 2 620-630
15. 782332 Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong W-P, Nabel GJ, Gomez PL Toxicol Sci 2006 91 2 610-619
16. 782333 Overcoming immunity to a viral vaccine by DNA priming before vector boosting. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ J Virol 2003 77 1 799-803
17. 869411 Fruit bats as reservoirs of Ebola virus. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, Swanepoel R Nature 2005 438 7068 575-576
18. 869427 Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: Epidemiologic and health control issues. Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ, Ngoc MT, Obiang PI, Lepage JP, Bertherat EJ, Benoni DD, Wickings EJ et al J Infect Dis 1999 179 Suppl 1 S65-S75
19. 870233 Catastrophic ape decline in western equatorial Africa. Walsh PD, Abernethy KA, Bermejo M, Beyers R, De Wachter P, Akou ME, Huijbregts B, Mambounga DI, Toham AK, Kilbourn AM, Lahm SA et al Nature 2003 422 6932 611-614
20. 870235 Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Rouquet P, Froment JM, Bermejo M, Yaba P, Délicat A, Rollin PE, Leroy EM Emerg Infect Dis 2005 11 2 283-290
21. 870236 Transmission of Ebola hemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ J Infect Dis 1999 179 Suppl 1 S87-S91
22. 870238 Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE J Infect Dis 2007 196 Suppl 2 S142-S147
23. 870240 Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Johnson E, Jaax N, White J, Jahrling P Int J Exp Pathol 1995 76 4 227-236
24. 870243 Attempts to develop a vaccine against Ebola fever. Chupurnov AA, Chernukhin IV, Ternovoǐ VA, Kudoiarova NM, Makhova NM, Azaev MSH, Smolina MP Vopr Virusol 1995 40 6 257-260
25. 870244 Inactivated vaccine for Ebola virus efficacious in guinea pig model. Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA Lancet 1980 2 8207 1294-1295
26. 870787 Evaluation in nonhuman primates of vaccines against Ebola virus. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB Emerg Infect Dis 2002 8 5 503-507
27. 870788 Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D et al Vaccine 2003 21 25-26 4071-4080
28. 871573 Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM Virology 2006 346 2 394-401
29. 871588 Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM et al Nat Med 2005 11 7 786-790
30. 871595 Successful topical respiratory tract immunization of primates against Ebola virus. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A J Virol 2007 81 12 6379-6388
31. 871623 Filovirus-like particles as vaccines and discovery tools. Warfield KL, Swenson DL, Demmin G, Bavari S Expert Rev Vaccines 2005 4 3 429-440
32. 871626 Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S Vaccine 2005 23 23 3033-3042
33. 871627 Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Ye L, Lin J, Sun Y, Bennouna S, Lo M, Wu Q, Bu Z, Pulendran B, Compans RW, Yang C Virology 2006 351 2 260-270
34. 871630 Ebola virus-like particles protect from lethal Ebola virus infection. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S Proc Natl Acad Sci USA 2003 100 26 15889-15894
35. 871631 Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF Vaccine 2000 19 1 142-153
36. 871632 Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J J Virol 2001 75 23 11677-11685
37. 871633 Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Wilson JA, Bray M, Bakken R, Hart MK Virology 2001 286 2 384-390
38. 871637 The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever. Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskii VP Vopr Virusol 1994 39 2 82-84
39. 871639 An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J et al Hum Gene Ther 1996 7 10 1205-1217
40. 871648 A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, Letvin NL et al J Virol 2005 79 14 8828-8834
41. 871649 Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ Nat Med 2000 6 8 886-889
42. 871661 Ebola virus pathogenesis: Implications for vaccines and therapies. Sullivan N, Yang ZY, Nabel GJ J Virol 2003 77 18 9733-9737
43. 871663 Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, Dichek DA J Clin Invest 1997 99 2 209-219
44. 871666 Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B et al J Imunol 2004 172 10 6290-6297
45. 871670 AIDS research. Did Merck's failed HIV vaccine cause harm? Cohen J Science 2007 318 5853 1048-1049
46. 876881 Effective post-exposure treatment of Ebola infection. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, Hensley LE et al PUBLIC LIBRARY SCI PATHOGENs 2007 3 1 54-61
47. 876886 Development of a recombinant simian foamy virus vector expressing Ebola virus glycoprotein: Preliminary studies aimed at producing a vaccine for great apes. Smith J, Roell J, Otten R, Jackson E, Rollin P, Fredeking T FILOVIRUSES: REC ADV FUT CHALL 2006 September 17-19
48. 876887 Protective immunity to Ebola infection by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. Olinger GG, Hart MK FILOVIRUSES: REC ADV FUT CHALL 2006 September 17-19
49. 876890 Development of a recombinant vaccine against filovirus infection-immunogenicity of soluble viral antigens and protective efficacy of candidate vaccine formulations in the mouse model of Ebola Zaire. Lehrer AT, Coller B, Clements DE, Aniya CS, Lieberman MM FILOVIRUSES: REC ADV FUT CHALL 2006 September 17-19
50. 876891 Circumventing the presence of pre-existing immunity to adenovirus vaccine vector with new serotypes or immunization strategies. Kobinger G FILOVIRUSES: REC ADV FUT CHALL 2006 September 17-19
51. 892823 Emergency preparedness and response: Bioterrorism agents/diseases. Centers for Disease Control and Prevention COMPANY WORLD WIDE WEB SITE 2008 April 03
52. 892839 Vaccine research efforts for filoviruses. Hart MK INT J PARASITOL 2003 33 5-6 583-595
53. 898131 Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS et al J IMMUNOL 2005 174 11 7179-7185
54. 898135 Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S J INFECT DIS 2007 196 Suppl 2 S430-S437
55. 898137 Towards the preparative and large-scale precision manufacture of virus-like particles. Pattenden LK, Middelberg AP, Niebert M, Lipin DI TRENDS BIOTECHNOL 2005 23 10 523-529
56. 898140 Outbreaks of filovirus hemorrhagic fever: Time to refocus on the patient. Bausch DG, Feldmann H, Geisbert TW, Bray M, Sprecher AG, Boumandouki P, Rollin PE, Roth C J Infect Dis 2007 196 Suppl 2 S136-S141
57. 898141 Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. Bausch D, Sprecher AG, Jeffs B, Boumandouki P Antiviral Res 2008 78 1 150-161
58. 898142 FDA perspective on antivirals against biothreats: Communicate early and often. Roberts R, Styrt B, McCune S Antiviral Res 2008 78 1 60-63
59. 898703 Epidemic and pandemic alert and response (EPR): Ebola haemorrhagic fever in Uganda. World Health Organization COMPANY WORLD WIDE WEB SITE 2007 November 30
60. 898916 Safety and biodistribution of a multiple strain Ebola gene DNA plasmid vaccine (VRC-EBODNA012-00-VP) in the New Zealand White rabbit. Manetz TS, Stein J, Sheets R, Wolfe G, Duffy C, Gomez P TOXICOLOGIST 2004 78 Suppl 1 Abs 78
61. 898926 Chapter 8: Ebola, Marburg, Lassa, and other hemorrhagic fevers. Bausch DG EMERGING INFECTIOUS DISEASES: TRENDS ISSUES 2nd Edition (EDS: LASHLEY FR, DURHAM JD) Springer Publishing, New York, NY, USA 2007 133-157
62. 898934 Chapter 109: Overview of viral hemorrhagic fevers. Peters CJ, Zaki SR TROPICAL INFECT DISEASES: PRINCIPLES, PATHOGENS, PRACT 2nd Edition (EDS: GUERRANT RL, WALKER DH, WELLER PF) Churchill Livingstone, Oxford, UK 2006 726-733
63. 898938 Chapter 4: Responding to epidemics of Ebola hemorrhagic fever: Progress and lessons learned from recent outbreaks in Uganda, Gabon, and Congo. Bausch D, Rollin P EMERGING INFECTIONS 6 6th Edition (EDS: SCHELD WM, MURAY BE, HUGHES JM) ASM Press, Washington, MD, USA 2004 35-57
64. 898940 Immunogenicity of prototype adenovirus-based Ebola vaccines in the absence and presence of pre-existing adenovirus immunity. Havenga M, Kostense S, ter Muelen J, Pau MG, Custers J, Koudstaal W KEYSTONE SYMP - BIOTERRORISM EMERG INFECT DIS 2004 123